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Abstract
Background: MicroRNAs (miRNAs) have been implicated in cancer initiation and progression via their ability to affect
expression of genes and proteins that regulate cell proliferation and/or cell death. Transcription of the three miRNA miR-34
family members was recently found to be directly regulated by p53. Among the target proteins regulated by miR-34 are
Notch pathway proteins and Bcl-2, suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer
stem cells.
Methodology/Principal Findings: We examined the roles of miR-34 in p53-mutant human pancreatic cancer cell lines
MiaPaCa2 and BxPC3, and the potential link to pancreatic cancer stem cells. Restoration of miR-34 expression in the
pancreatic cancer cells by either transfection of miR-34 mimics or infection with lentiviral miR-34-MIF downregulated Bcl-2
and Notch1/2. miR-34 restoration significantly inhibited clonogenic cell growth and invasion, induced apoptosis and G1 and
G2/M arrest in cell cycle, and sensitized the cells to chemotherapy and radiation. We identified that CD44+/CD133+
MiaPaCa2 cells are enriched with tumorsphere-forming and tumor-initiating cells or cancer stem/progenitor cells with high
levels of Notch/Bcl-2 and loss of miR-34. More significantly, miR-34 restoration led to an 87% reduction of the tumor-
initiating cell population, accompanied by significant inhibition of tumorsphere growth in vitro and tumor formation in vivo.
Conclusions/Significance: Our results demonstrate that miR-34 may restore, at least in part, the tumor suppressing function
of the p53 in p53-deficient human pancreatic cancer cells. Our data support the view that miR-34 may be involved in
pancreatic cancer stem cell self-renewal, potentially via the direct modulation of downstream targets Bcl-2 and Notch,
implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination.
Restoration of miR-34 may hold significant promise as a novel molecular therapy for human pancreatic cancer with loss of
p53–miR34, potentially via inhibiting pancreatic cancer stem cells.
Citation: Ji Q, Hao X, Zhang M, Tang W, Meng Y, et al. (2009) MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells. PLoS ONE 4(8): e6816.
doi:10.1371/journal.pone.0006816
Editor: Eric J. Bernhard, National Cancer Institute, United States of America
Received January 22, 2009; Accepted August 5, 2009; Published August 28, 2009
Copyright:  2009 Ji et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by NIH grants CA121830-01, CA128220-01 and CA134655-01A1 (L. Xu.), and by NIH through the University of
Michigan’s Cancer Center Support Grant (P30 CA46592). JTD is a University of Michigan Undergraduate Research Opportunity Program (UROP) student. The
funders had no role in the design and conduct of the study, in the data collection, analysis and interpretation, and decision to publish, review, approval, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: liangxu@umich.edu
¤ Current address: Institute of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing, People’s Republic of China
. These authors contributed equally to this work.
Introduction
MicroRNAs (miRNAs) are a conserved class of non-coding 20–
22 nt small RNAs that regulate gene and protein expression by
binding to mRNA leading to mRNA degradation or inhibition of
translation [1,2]. miRNAs likely regulate diverse biological
processes, including tissue differentiation and maintenance, and
have contributing roles in varied disease processes, including
cancer [2,3,4]. Emerging evidence suggests that miRNAs also play
an essential role in stem cell self-renewal and differentiation by
negatively regulating the expression of certain key genes involved
in self-renewal and survival, so-called ‘‘stem cell genes’’ [1,2,4,5].
Recently, the three members of the miR-34 family were found to
be directly regulated by p53 and the functional activity of miR-34
indicated a potential role as a tumor suppressor [6,7,8,9,10,11,12].
We previously reported that the Bcl-2 protein is regulated directly
by miR-34 [10]. The report from He et al. indicated that ectopic
expression of miR-34 induces cell cycle arrest in both primary and
tumor-derived cell lines, which is consistent with the ability of
miR-34 to downregulate a program of genes promoting cell cycle
progression [11]. We have recently shown that expression of miR-
34s is dramatically reduced in p53-mutant gastric cancer cells and
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growth [6]. Loss of miR-34 has been linked to chemoresistance of
cancer [13]. miR-34a has been reported to be involved in p53-
mediated apoptosis in colon cancer and pancreatic cancer [8,9].
Chang et al. reported that 15 pancreatic cancer cell lines have at
least a 2-fold reduction in miR-34a expression as compared to
expression in normal pancreatic ductal epithelial cell lines [8].
Taken together, the published studies suggest miR-34 family
members may have tumor suppressor function downstream of
p53. In addition, because more than 50% of primary human
cancers have mutations inactivating p53 function, the findings
provided impetus to explore the functional restoration of miR-34
as a novel approach to inhibit cancers with p53 loss-of-function.
Another potential role for miR-34 in cancer initiation and
progression may be a link to tumor-initiating cells or cancer stem
cells (CSC). It has been reported that miR-34 targets Notch, c-Met
and Bcl-2, genes involved in the self-renewal and survival of cancer
stem cells [10,11,14]. At present, the linkages between p53, the
downstream target miR-34 and presumptive pancreatic cancer
stem cells are unknown. In the current study, we have examined
the effects of functional restoration of miR-34 by miR-34 mimics
and lentiviral miR-34a on human p53-mutant pancreatic cancer
MiaPaCa2 cells, as well as the potential link to the pancreatic
cancer stem cell self-renewal. Delineating the role of miR-34 in
regulation of cell growth and tumor progression, and its potential
link to tumor-initiating cells or cancer stem cells may provide a
basis for exploring its potential as a novel treatment strategy.
Materials and Methods
Cell culture and reagents
Human pancreatic cancer cell lines and the normal human lung
fibroblast cell line WI-38 were purchased from American Type
Culture Collection and cultured in DMEM (HyClone, Logan, UT),
supplemented with 10% fetal bovine serum (FBS; HyClone, Logan,
UT). miRIDIAN miRNA miR34a,b,c mimics and negative control
miRNA mimic (NC mimic), miRIDIAN miR-34 inhibitors and
negative controls were obtained from Dharmacon(Chicago,IL) [6].
Bcl-2 39UTR luciferase reporter plasmid or its mutant have been
reported previously [10]. qRT-PCR primers and antibodies for
Western blot are described in our recent publication [6].
Transfection of miR-34 mimics
MiaPaCa2 cells were transfected 24 hr after being seeded in 6-
well plates. miRNA mimics (100 pmol) in 200 ml of serum-free,
antibiotic-free, medium were mixed with 5 ml of Lipofectamine
2000 transfection reagent (Invitrogen, Carlsbad, CA) dissolved in
200 ml of the same medium and allowed to stand at room
temperature for 20 min. The resulting 400 ml transfection
solutions were then added to each well containing 1.6 ml of
medium. Six hr later, the cultures were replaced with 2 ml fresh
medium supplemented with 10% FBS and antibiotics. For
Western blot, cells were collected after an additional 48 hr.
Lentiviral miR-34a infection
The feline immunodeficiency virus (FIV) lentiviral system
expressing miR-34a (miR-34a-MIF) or vector control (MIF), as
well as a lentiviral packaging system, were purchased from System
Biosciences (SBI, Mountain View, CA). MiaPaCa2 and BxPC3
cells were infected with the FIV lentiviral system expressing miR-
34a (miR-34a-MIF) or vector control (MIF), and the infected cells
were selected via antibiotic resistance (Zeocin 50 mg/mL, Invitro-
gen), as we recently described[6].
miR-34 Bcl-2-39UTR reporter assay
MiaPaCa2 cells were transfected in 6-well plates with 2 mgo f
Bcl-2 39UTR luciferase reporter plasmid or its mutant [6,10], and
2 mg of the control b-galactosidase plasmid, per well, using
Lipofectamine 2000 (Invitrogen). Cells were also co-transfected with
100 pmol of each miR-34 mimic or NC mimic, as indicated, using
Lipofectamine 2000. Luciferase assays were performed 24 hr after
transfection using Bright-Glo Luciferase Assay System (Promega).
Luciferase activity was normalized relative to b-galactosidase activity
detected by the b-galactosidase Assay System (Promega). In each
case, mutant Bcl-2 39UTR indicates the introduction of alterations
into the seed complementary sites of Bcl-2 39UTR [10].
Colony formation and clonogenic assay
For colony formation assay, cells were transfected with miR-34
mimics or NC mimic for 24 hr, and then seeded in a 6-well plate
in triplicate. 0.2 ml FBS was added per well on Day 5. After 9–10
days incubation, plates were gently washed with PBS and stained
with 0.1% of crystal violet. Colonies with over 50 cells were
manually counted. Plating efficiency was calculated by dividing the
number of colonies formed in the treated group by that in control.
For clonogenic survival assay, cells were transfected with miR-34
mimics or NC mimic for 24 hr, and then seeded in 6-well plates in
triplicate at the desired cell density (200,10,000 cells/well),
followed by X-ray radiation. The cell survival curves were plotted
using a linear-quadratic model and the radiation enhancement
ratio (ER) was calculated as we previously described [15,16,17].
Quantitative real-time RT-PCR (qRT-PCR)
qRT-PCR was performed to determine the expression levels of
potential miR-34 target genes [6]. Twenty-four hr after miR-34
mimic transfection of MiaPaCa2 cells with miR-34 mimics
(100 pmol per well in 6-well plates), the expression of potential
target genes was measured by qRT-PCR with SYBR Green PCR
System (TaqMan). Briefly, total RNA was extracted from the
transfected cells using TRIZOL (Invitrogen) according to the
manufacturer’s instructions. Reverse transcription was performed
by using a TaqMan Reverse Transcription Kit (Applied
Biosystems). For qRT-PCR, 1 ml of gene primers with SYBR
Green (Applied Biosystems) in 20 ml of reaction volume was
applied. Primers were designed as: Bcl-2, forward, 59-CAT GCT
GGG GCC GTA CAG-39, reverse, 59-GAA CCG GCA CCT
GCA CAC-39; HMGA2, forward, 59-TTT GTA ATC CCT TCA
CAG TCC-39, reverse, 59-TTT CTC ACC CGC CCA C-39;
Notch1, forward, 59-ATC CAG AGG CAA ACG GAG-39,
reverse, 59-CAC ATG GCA ACA TCT AAC CC-39; Notch2,
forward, 59-GGA CCC TGT CAT ACC CTC TT-39, reverse, 59-
CAT GCT TAC GCT TTC GTT TT-39; Notch3, forward, 59-
TGA TCG GCT CGG TAG TAA TG-39, reverse, 59-CAA CGC
TCC CAG GTA GTC A-39; Notch4, forward, 59-TGC GAG
GAA GAT ACG GAG TG-39, reverse, 59-CGG GAT CGG AAT
GTT GG-39; b-actin, forward, 59-ATG CAG AAG GAG ATC
ACT GC-39, reverse, 59-TCA TAG TCC GCC TAG AAG CA-
39. Allreactions with TaqMan UniversalPCR Master Mix (Applied
Biosystems) were performed on the Mastercycler Realplex 2
(Eppendorf, Westbury, NY). Target gene mRNA levels were
normalized to Actin mRNA according to the following formula:
[2ˆ2(CT
target 2 CT
Actin)] 6 100%, where CT is the threshold
cycle. The relative expression was calculated by dividing the
normalized target gene expression of the treated sample with that of
the untreated control, with the value from NC mimic set as 1
arbitrary unit. For the target genes expression in the sorted cells,
data were normalized to that of Actin (set Actin=1000 arbitrary
unit).
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Caspase activation in the transfected MiaPaCa2 cells was
determined following the instructions of a Caspase-3 activation
assay kit (BioVision, Mountain View, CA). Twenty-four hr after
transfection, cells were lysed and the whole cell lysates (20 mg)
were incubated with 25 mM fluorogenic substrate DEVD-AFC in
a reaction buffer (containing 5 mM DTT) at 37uC for 2 hr.
Proteolytic release of AFC was monitored at lex=405 nm and
lem=500 nm using a fluorescence microplate reader (BMG
LABTECH, Durham, NC). Relative caspase-3 activation was
calculated by normalizing the fluorescence signal in each treated
sample with that of NC mimic or MIF control set as 100 arbitrary
unit [16].
Cell cytotoxicity assay
MiaPaCa2 cells were transfected with miR-34 mimic or NC
mimic for 24 hr, plated in 96-well plates (5,000 cells/well), and
treated with serially diluted chemotherapeutic agents, in tripli-
cates. After 96 h incubation, 20 ml/well CCK-8 reagent was
added and incubated at 37uC for 1–3 hr. Optical density was
measured at 450 nm and 650 nm using a microplate reader (BMG
LABTECH, Durham, NC). IC50, the drug concentration that
inhibits 50% cell growth was calculated by GraphPad Prism 5.0
(San Diego, CA) as we described previously [18].
Cell cycle and apoptosis analysis
For cell cycle and apoptosis analysis by flow cytometry,
MiaPaCa2 cells were transfected with miR-34 mimics or NC
mimic in 6-well plates, trypsinized 24 hr later and washed with
phosphate-buffered saline, and fixed in 70% ethanol on ice. After
centrifugation, cells were stained with 50 mg/ml propidium iodide
and 0.1 mg/ml RNase A, and analyzed by flow cytometry using a
FACStar Plus
TM. Each histogram was constructed with the data
from at least 5,000 events. Data were analyzed to calculate the
percentage of cell population in each phase using the CellQuest
software, as well as the % of cells in sub-G1 (Becton Dickinson)
[18].
CD44 and CD133 staining and cell sorting
MiaPaCa2 cells were incubated with PE-conjugated anti-
human CD133/1 antibody and APC-conjugated anti-human
CD44 antibody (Miltenyi Biotec, Aubum, CA, USA) in PBS
containing 2% FBS. Isotype-matched mouse immunoglobulin
served as controls. For flow cytometry, samples were analysed
using a FACSCalibur flow cytometer and CellQuest software (BD
Biosciences, San Jose, CA, USA). For cell sorting by flow
cytometry, samples were analysed and sorted on a BD FACSVan-
tage SE (BD Biosciences). Aliquots of CD133
+ and CD133
2 sorted
cells were evaluated for purity with a FACSCalibur machine and
CellQuest software (BD Biosciences), using PE-conjugated anti-
human CD133/2 antibody (Miltenyi Biotec) [19].
Tumorsphere culture
The sorted MiaPaCa2 cells were suspended in serum-free
culture medium DMEM containing 1% N2 supplement, 2% B27
supplement, 1% antibotic-antimycotic (Invitrogen), 20 ng/ml
human FGF-2 (Sigma), and 100 ng/ml EGF (Invitrogen), and
plated in 24-well ultra-low attachment plates (Corning) 2,000 cells
per well. 7–10 days later, plates were analyzed for tumorsphere
formation and were quantified using an inverted microscope
(Olympus) at 100X, 200X, and 4006 magnifications. For
subsequent quantification of cell numbers per tumorsphere,
tumorspheres were collected with a 40 mm sieve (BD Biosciences,
San Jose, CA) and disassociated with trypsin to make a single cell
suspension. The viable cells were then counted using trypan blue
exclusion.
Animal model and in vivo tumor formation study
Five- to six-week old female athymic NCr-nu/nu nude mice were
purchased from NCI. MiaPaCa2 cells were transfected with miR-
34a mimic or NC mimic for 24 hr. Cells were collected and
inoculated into nude mice subcutaneously (s.c.) on both flanks, after
alcohol preparation of the skin, using a sterile 22-gauge needle with
0.2 ml cell suspension of 1610
6 cells, with manual restraint. The
tumor sizes were measured using a caliper. Tumor volume was
calculated using the formula: (length6width
2)/2. On Day 38, all
tumors were collected to measure the tumor weights. All animal
experiments were done according to the protocol approved by
University of Michigan Guidelines for Use and Care of Animals.
Statistical analysis
Two-way ANOVA and two-tailed t-tests were employed to
analyze the in vitro and in vivo data using Prism 5.0 software
(GraphPad, San Diego, CA). P,0.05 was defined as statistically
significant.
Results
Expression of miR-34s in human pancreatic cancer cell
lines
We examined a series of human pancreatic cancer cell lines,
MiaPaCa2, BxPC3, Capan1, Capan2, Panc-1, and the normal
human lung fibroblast cell line WI-38, for miR-34a,b,c expression.
We also assessed in parallel the expression of presumptive miR-34-
regulated target genes and proteins, using the primers and
methods as we described recently [6]. MiaPaCa2 and BxPC3
cells have very low expression levels of both primary and mature
miR-34a,b,c but high levels of the miR-34 target genes BCL2 and
Notch1, and different levels of Notch2–4 (Figure 1). They also have
low expression levels of p21 (Figure 1C), another mRNA target of
p53, consistent with the cell line’s p53-mutant status. Based on
these data and our observation that they are highly tumorigenic
and reproducibly form tumorspheres in vitro, we chose the two cell
lines for the current study.
miR-34 restoration by transfection of MiaPaCa2 cells with
miR-34 mimics
To investigate the effects of miR-34 restoration on pancreatic
cancer cells, we transfected the MiaPaCa2 cells with miR-34
mimics or non-specific control miRNA mimic (NC mimic).
Western blot analysis (Figure 2A) showed that transfection of
miR-34 mimics downregulated expression of target genes, Bcl-2,
Notch1 and Notch2 at the protein level, but had no effect on Bcl-
xL and Mcl-1 expression, indicating the target gene knock-down
by miR-34 mimics affects transcripts harbouring miR-34 target
sites. miR-34a, miR-34b and miR-34c mimics all had similar
activities. Figure 2B shows the qRT-PCR analysis of the potential
target genes; miR-34 mimics potently inhibited BCL2 and Notch1
gene expression, consistent with the Western blot data. They also
inhibited expression of p21 (Figure 2B), another target of p53,
but have limited effect on Notch3 and cMET. Interestingly, the
Notch2 expression inhibition at the protein level by miR-34 was
not accompanied by inhibition at the mRNA level, in agreement
with previous reports that miRNA inhibits target gene expression
post-transcriptionally, with or without mRNA degradation
[11,20].
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functional, we carried out the Bcl-2 39UTR reporter assay as we
recently described [6,10]. The transfected miR-34 mimics
inhibited the luciferase reporter gene expression, which is
controlled by Bcl-2 39UTR in the promoter region
(Figure 2C). However, mutation in the Bcl-2 39UTR comple-
mentary to the miR-34 seed sequence abolished this effect,
indicating that the observed activity is sequence-specific. The
results demonstrate that the transfected miR-34s are functional
and confirm that Bcl-2 is a direct target of miR-34, consistent
with earlier reports [8,10,21].
To evaluate the long-term effects of the miR-34 restoration, we
also employed a lentiviral system to express miR-34a. The feline
immunodeficiency virus lentiviral system expressing miR-34a
(miR-34a-MIF), or vector control (MIF), was used to infect
MiaPaCa2 and BxPC3 cells and the infected cell population was
selected via Zeocin resistance [6]. Figure S1 shows the
characterization of expression changes in the miR-34a-MIF cells.
Western blot analysis revealed that Bcl-2 protein was down-
regulated in miR-34a-MIF cells as compared with the MIF vector
control cells (Figure S1 A), consistent with qRT-PCR analysis of
the Bcl-2 mRNA level (Figure S1 B). Bcl-2 39UTR Luciferase
Reporter Assay showed that the miR-34a is functional in the miR-
34a-MIF cells (Figure S1 C).
miR-34 restoration inhibits MiaPaCa2 cell clonogenic
growth and leads to caspase-3 activation and apoptosis
After validating that the transfected miR-34 mimics were
functional, we carried out a clonogenic assay to examine the effects
of miR-34 restoration on cell growth. As shown in Figure 3A–B,
miR-34 restoration significantly inhibited the clonogenic cell
growth, with miR-34a mimic inducing .80% inhibition of colony
formation compared to NC mimic (18.363.8 colonies/well vs.
95.361.8% colonies/well). Similar results were observed in the
miR-34a-MIF cells which grew slower than MIF control cells, as
indicated by both the significantly reduced number of Trypan
Blue-excluding viable cells in the cell growth assay (Figure S1 D)
and the reduced colony formation (Figure S1 E). We also
examined the effect of inhibition of endogenous miR-34 on cell
growth by miRIDIAN miR-34 inhibitors. They are single-stranded
chemically enhanced oligonucleotides that can effectively inhibit
the endogenous mature miR-34. miR-34 inhibitors induced an
almost 20% increase in clonogenic growth as compared with
control (120.362.9 colonies/well vs. 95.361.8 colonies/well)
(Figure 3A–B). We also carried out a cell invasion assay in
MiaPaCa2 cells with miR-34 restoration by both miR-34a mimic
and miR-34a-MIF. miR-34 significantly inhibited the invasion
potential of MiaPaCa2 cells (Figure S2). Our results demonstrate
that miR-34 is involved in MiaPaCa2 cell growth; miR-34
Figure 1. Expression of Bcl-2 family of proteins and miR-34s in human pancreatic cancer cell lines as well as normal human
fibroblast cells WI-38. A, Western blot analysis. B, qRT-PCR analysis of relative expression levels of miR-34s. C, qRT-PCR analysis of the expression
levels of miR-34 target genes in human pancreatic cancer cell lines as well as normal human fibroblast WI-38 cells. The cells were lyzed to extract total
RNA for qRT-PCR, data were normalized to that of Actin and the relative levels are shown (Actin=1000). Note p21 is a target gene of p53.
doi:10.1371/journal.pone.0006816.g001
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endogenous miR-34 by miR-34 inhibitors promotes the growth.
Our data are consistent with the reported tumor suppressor
function of miR-34 [6,8,9,11,22].
Since p53 tumor suppressor function is mediated in part via
induction of apoptosis [23,24], we examined the effect of miR-34
restoration on apoptosis-induction in MiaPaCa2 cells transfected
with miR-34 mimics. As shown in Figure 3C, transient
transfection of miR-34 mimics resulted in significantly increased
activation of caspase-3, a key indication of the cells undergoing
apoptosis [25]. We also evaluated the effect of miR-34 mimics on
cell cycle. miR-34 mimics resulted in significant G1 and G2/M
arrest and a reduction of cells in S phase (Figure 3D), consistent
with other reports on miR-34 restoration in various cancer models
[6,7,8,10,11,21,22,26]. This effect on cell cycle is similar to that of
p53 restoration as we previously reported [23,24,27,28], indicating
that miR-34 restoration can exert effects akin to restoration of p53
tumor suppressor function, at least in part, in the cells with p53
loss of function.
miR-34 restoration sensitizes MiaPaCa2 cells to chemo-
and radiotherapy
Next, we examined whether miR-34 restoration could sensitize
the pancreatic cancer cells with a high level of endogenous Bcl-2
expression to chemo- and radiotherapy. The WST-1-based
cytotoxicity assay was used as we recently described [6,18] to
evaluate the cells’ response to three chemotherapeutic agents,
docetaxel, cisplatin and gemcitabine, all of which are currently used
for pancreatic cancer chemotherapy. As shown in Figure 4A, miR-
34 restoration in MiaPaCa2 cells rendered the cells 2–3-fold more
sensitive to the chemotherapeutic agents, as compared with the
vector control cells, based on IC50 data. In apoptosis assays, miR-
34a restoration significantly increased Gemcitabine or radiation
induced caspase-3 activation (Figure 4B) and sub-G1 cells
(Figure 4C). We have also carried out clonogenic assay, miR-34a
mimic sensitized MiaPaCa2 cells to X-ray radiation, with a
radiation enhancement ratio (ER)=1.3 (Figure 4D). Our data
demonstrate that miR-34 restoration can overcome chemo-/
radioresistance of the pancreatic cancer cells that have high levels
Figure 2. Restoration of miR-34 down-regulates target genes’ expression. A, miR-34 restoration down-regulates target proteins Bcl-2,
Notch1 and Notch2, no effects on Mcl-1. MiaPaCa2 cells were transfected with miR-34 mimics or non-specific control miRNA mimic (NC mimic)
(100 pmol per well in 6-well plates by Lipofectamine 2000) for 48 hours, then collected for Western blot analysis. B, Quantitative real-time PCR
analysis of the potential target genes’ mRNA levels after miR-34 mimic transfection in MiaPaCa2 cells. **P,0.01, ***P,0.001, Student’s t-test, n=2. C,
Bcl-2 39UTR Luciferase Reporter Assay shows that the transfected miR-34 mimics are functional. MiaPaCa2 cells were co-transfected with the Bcl-2
39UTR Luciferase Reporter or its mutant, b-gal vector, together with either miR-34 mimics or NC mimic. Luciferase assay was performed 24 hrs after
transfection using Bright-Glo Luciferase Assay System. Luciferase activity was normalized relative to b-gal activity. Error bar indicates s.e.m.
doi:10.1371/journal.pone.0006816.g002
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2 for survival and resistance to therapy.
CD44+/CD133+ cells are tumorsphere-forming and
tumor-initiating cells with high Bcl-2 and loss of miR-34
expression
To investigate the potential effect of miR-34 restoration on
tumor-initiating cells in the MiaPaCa2 cell line, we first examined
the tumor-initiating cell or cancer stem cell population in
MiaPaCa2 cells with various cell surface markers. Both CD44
[29] and CD133 [19,30] have been used as markers to identify the
pancreatic cancer stem cells from human tumor tissues. However,
there is no report on the cancer stem cells in MiaPaCa2 cells. We
evaluated the CD44 and CD133 status in MiaPaCa2 cells by
immunofluorescent stainingand FACS sorting. About 60% cells are
CD44+ and 3–5% cells are CD133+, however, only 1–2% cells are
CD44+/CD133+ double-positive (Q2 in Figure 5A). To examine
the self-renewal potential of the cells with different surface marker
profiles, we undertook the tumorsphere culture of the sorted cells in
a special ultra-low attachment culture plate with conditional
medium for tumorsphere culture [29]. Seven to ten days later, the
CD44+/CD133+ double-positive MiaPaCa2 cells grew typical
tumorspheres but not the CD442/CD1332 double-negative cells,
whereas CD44+/CD1332 or CD442/CD133+ single-positive
cells had fewer and smaller spheres (Figure 5B–C). A represen-
tative tumorsphere from CD44+/CD133+ cells is shown in
Figure 5B (the insert). We also carried out a limiting dilution
tumor-initiation assay in nude mice using the sorted cells, and data
are summarized in Table 1. CD442/CD1332 cells did not form
tumor, whereas 1610
4 CD44+/CD133+ cells formed tumor in 4
out of 4 mice, 1610
3 CD44+/CD133+ cells formed tumor in 2 out
of 4 mice, and no tumor formed with 1610
2 cells. Thus, our data
demonstrate that the CD44+/CD133+ double-positive MiaPaCa2
cells are enriched with tumor-initiating cells or cancer stem/
progenitor cells capable of self-renewal, but the CD442/CD1332
double-negative population contains no such cells. Our results also
Figure 3. Restoration of miR-34 inhibits the clonogenic growth of MiaPaCa2 cells, whereas inhibition of miR-34 promotes cell
growth. MiaPaCa2 cells were transfected with miR-34 mimics or inhibitors, 24 hr later the cells were seeded in 6-well plates (200 cells/well, in
triplicates). After 12–14 days incubation, the plates were gently washed with PBS and stained with 0.1% crystal violet. A, representative pictures of the
colonies. B, Colonies with over 50 cells were counted. C, Restoration of miR-34 leads to caspase-3 activation. Caspase-3 activation assay was carried
out as described in in Materials and Methods. Fold increase of fluorescence signal was calculated by dividing the normalized signal in each treated
sample with that in the untreated control. **P,0.01, ***P,0.001, Student’s t-test, n=3. D, Cell cycle distribution of MiaPaCa2 cells transfected with
miR-34 mimics. Cell cycle analysis was performed 1 day after transfection. Cells were stained with propidium iodide after ethanol fixation and
analyzed by flow cytometry.
doi:10.1371/journal.pone.0006816.g003
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cells in the MiaPaCa2 cell line.
Next, we carried out qRT-PCR analysis of the sorted MiaPaCa2
cells to assess whether there is any difference in these populations as
to the expression levels of miR-34 and its target genes. As shown in
Figure 5D, the CD44+/CD133+ (Q2) cells have a high level of
Bcl-2 expression but loss of miR-34a/b/c as compared with
CD442/CD1332 (Q3) cells or the unsorted (total) cells. There is
an inverse correlation in the expression levels of miR-34 and Bcl-2
in Q2 versus Q3, e.g., Q2 cells (with enriched cancer stem cells)
have high Bcl-2 and low miR-34, Q3 cells (non-tumorigenic cells)
have low Bcl-2 and high miR-34 levels. Our results are consistent
with the notion that Bcl-2 is a direct target of miR-34 and miR-34
potently inhibits Bcl-2 expression. More importantly, our results
demonstrate for the first time that the CD44+/CD133+ tumor-
initiating cells, or pancreatic cancer stem cells, have a low level of
miR-34 accompanied by a high level of Bcl-2, suggesting a potential
link of miR-34 and its target Bcl-2 to pancreatic cancer stem cells.
miR-34 restoration leads to a significant reduction of
CD44+/CD133+ cells and inhibition of tumorsphere
growth
Our above results have shown that miR-34 potently inhibits
Bcl-2 expression and cell growth and increases cell death and
response to chemo-/radiotherapy in the overall population of
MiaPaCa-2 cells. We have also shown that the CD44+/CD133+
tumorsphere-forming and tumor-initiating cells have high Bcl-2
and loss of miR-34 expression, indicating that miR-34 and its
target Bcl-2 might be involved in cancer stem cells. To investigate
the potential role of miR-34 in pancreatic cancer stem cells, we
examined whether miR-34 restoration could inhibit the CD44+/
CD133+ cells and their self-renewal potential. Figure 6A shows
that miR-34a restoration significantly decreased the CD44+/
CD133+ cells (0.5860.08% versus MIF control 1.9360.19%,
P=0.022, n=2), an 87% reduction (Figure 6B). This miR-34a-
induced reduction of the CD44+/CD133+ cells was accompanied
by reduced tumorsphere formation and smaller size of the
Figure 4. Restoration of miR-34 sensitizes MiaPaCa2 cells to chemotherapy and radiation. A, miR-34 restoration sensitizes the cells to
chemotherapeutic agents. The MTT-based cytotoxicity assay was carried out using the Zeocin-resistant stable MiaPaCa2-miR-34a-MIF and MiaPaCa2-
MIF cells. B, miR-34 restoration increases caspase-3 activation induced by gemcitabine or X-ray radiation in MiaPaCa2 cells. Relative caspase-3
activation was calculated by normalizing the fluorescence signal in each treated sample with that of the NC mimic or MIF control as 100. *P,0.05,
***P,0.001, Student’s t-test, n=3. C, miR-34 restoration increases radiation-induced apoptosis in MiaPaCa-2 cells. Cells were transfected with miR-34a
mimic or NC mimic. 24 hr later, the cells were subjected to X-ray radiation. The cells were collected after another 48 hr, stained with propidium iodide
after ethanol fixation, and analyzed by flow cytometry for the % of cells in sub-G1 phase. *P,0.05, Student’s t-test, n=2. D, miR-34 restoration
radiosensitized MiaPaCa-2 cells. The clonogenic assay was carried out as described in Materials and Methods Data are shown as mean +/2 SD (n=3).
doi:10.1371/journal.pone.0006816.g004
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reduction of Bcl-2 expression in the CD44+/CD133+ tumor-
sphere-forming cells (Figure 6D). Interestingly, although miR-34a
inhibited the Bcl-2 expression in the total population as well as in
both the sorted CD44+/CD133+ cells and CD442/CD1332
cells, the effect of miR-34a on the CD44+/CD133+ population
was most dramatic (miR-34a 1.6561.15 vs. MIF 37.868.3, almost
a 23-fold reduction at Bcl-2 mRNA level, compared with that of
the total populations: miR-34a 0.860.01 vs. MIF 1.460.03, a
43% reduction) (Figure 6D). Similar results on tumorspheres
were observed with the total cells from the miR-34a-MIF cells
(Figure S3). Our data provide the first evidence that miR-34 is
able to inhibit CD44+/CD133+ tumorsphere-forming and tumor-
initiating cancer stem cells in p53-mutant pancreatic cancer,
implying that miR-34 might play a role in the self-renewal of
pancreatic cancer stem cells. Similar results were also observed in
BxPC3 cells, where lentiviral miR-34a restoration significantly
inhibited the clonogenic growth (Figure 7A) and tumorspheres
(Figure 7B).
Figure 5. MiaPaCa2 CD44+/CD133+ cells are tumorsphere-forming cells that have high Bcl-2 and loss of miR-34. A, CD44 and CD133
staining of MiaPaCa2 cells. MiaPaCa2 cells were stained by anti-CD44-APC and anti-CD133-PE and sorted by FACS. Around 1–2% cells are CD44+/
CD133+ double-positive (Q2). B–C, Tumorsphere culture of the sorted cells. The sorted cells were plated for tumorsphere culture as described in
Materials and Methods. 7–10 days later, tumorspheres were counted (B). The insert shows a representative tumorsphere from CD44+/CD133+
MiaPaCa2 cells. C. Quantification of cell numbers per tumorsphere. Tumorspheres were collected with 40 um filter and dissociated with trypsin to
make a single cell suspension. Cells were counted with trypan blue exclusion and data are presented as number of cells per tumorsphere. CD44+/
CD133+ cells are tumorsphere-forming cells whereas CD442/CD1332 cells did not grow tumorspheres. *P,0.05, **P,0.01, ***P,0.001, Student’s t-
test, n=3. D, qRT-PCR analysis of the expression levels of miR-34 and target genes in the sorted MiaPaCa2 cells. The sorted cells were lyzed to extract
total RNA for qRT-PCR. The miR-34 expression data were normalized to that of Actin and the relative levels are shown (set unsorted cells=1). For the
target genes expression, data were normalized to that of Actin (set Actin=1000). CD44+/CD133+ (Q2) cells have high levels of Bcl-2 and Notch1 but
loss of miR-34a/b/c as compared with CD442/CD1332 (Q3) cells. *P,0.05, **P,0.01, ***P,0.001, Student’s t-test, n=2.
doi:10.1371/journal.pone.0006816.g005
Table 1. Tumor-initiation study.
Cells inoculated 1610
4 1610
3 1610
2
CD44+/133+ 4/4** 2/4 0/4
CD442/1332 0/4 0/4 0/4
MiaPaCa2 cells were stained and sorted for CD44+/CD133+ and CD442/CD1332
cells,andthens.q.inoculatedin nude mice. Dataarenumberof micewithtumors
formed/number of mice inoculated.
**P,0.01, Chi-square test.
doi:10.1371/journal.pone.0006816.t001
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formation in nude mice
We carried out studies to examine the effect of miR-34
restoration on tumor initiation in vivo. MiaPaCa2 cells were
transfected with miR-34a mimic or NC mimic for 24 hours. Cells
were collected and inoculated into female athymic nude mice
subcutaneously (s.c.). As shown in Figure 8A, miR-34a
restoration significantly inhibited MiaPaCa2 tumor formation in
vivo (miR-34a mimic 2/10 versus NC mimic 10/10, P,0.0001,
n=10). The average tumor sizes were also significantly smaller
than that with control miRNA (Figure 8B–C).
Discussion
Our results show that miR-34 restoration in human pancreatic
cancer MiaPaCa2 and BxPC3 cells inhibited the expression of
target genes, Bcl-2, Notch1 and Notch2; significantly inhibited
clonogenic cell growth and invasion; induced apoptosis and G1
and G2/M arrest; and sensitized the cells to chemotherapy and
radiation. Our study demonstrates that miR-34 may restore, at
least in part, the tumor suppressing function of p53 in p53-
deficient cancer cells. We have also identified that CD44+/
CD133+ MiaPaCa2 cells are enriched with tumorsphere-forming
and tumor-initiating cells or CSC with high levels of Notch/Bcl-2
and loss of miR-34s. More significantly, we show that miR-34
restoration led to an 87% reduction of the CD44+/CD133+ CSC,
accompanied by significant inhibition of tumorsphere growth in
vitro as well as tumor formation in vivo. Our data support the view
that miR-34 may be involved in pancreatic cancer stem cell self-
renewal, potentially via the direct modulation of downstream
targets Bcl-2 and Notch, implying that miR-34 may play an
important role in pancreatic cancer stem cell self-renewal and/or
cell fate determination, at least in the p53-mutant MiaPaCa2
model. These findings suggest that miR-34 mimics may hold
significant promise as a novel molecular therapy for human
pancreatic cancer with loss of p53–miR34, potentially via
modulating pancreatic cancer stem cells.
A potential advantage of miRNAs as therapeutics is that
miRNA can modulate multiple cellular pathways simultaneously
[6]. One major difference between miRNA and siRNA is that
Figure 6. Restoration of miR-34 by MIF lentiviral system decreases the CD44+/CD133+ MiaPaCa2 cells and inhibits tumorspheres
from the sorted CD44+/CD133+ cells. A–B, CD44 and CD133 FACS analysis of the MiaPaCa2-miR-34a-MIF and MiaPaCa2-MIF cells. miR-34a
restoration significantly reduced the CD44+/CD133+ cells. Values are mean6s.e.m, n=2. C, miR-34a restoration inhibits tumorspheres from the sorted
CD44+/CD133+ cells. The cell sorting and tumorsphere culture were as described in Materials and Methods. 7–10 days later, tumorspheres were
counted and the cell numbers per tumorsphere were quantified. Tumorspheres were collected with 40 um filter (BD) and dissociated with trypsin to
make a single cell suspension. Cells were counted with trypan blue exclusion and data are presented as number of cells per tumorsphere. *P,0.05,
Student’s t-test, n=3. D, qRT-PCR analysis of Bcl-2 mRNA levels in the sorted cells with or without miR-34a restoration. Data are shown as relative
mRNA levels normalized to that of Actin=1000 arbitrary units. Values are mean6s.d, n=2. miR-34a restoration led to almost 23-fold reduction of Bcl-
2 mRNA in CD44+/CD133+ cells, compared with 43% reduction in total population. **P,0.01, ***P,0.001, one-way ANOVA and Student’s t-test,
n=2.
doi:10.1371/journal.pone.0006816.g006
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while one miRNA can bind to multiple 39UTRs of target mRNAs
via 6–8 nucleotides root-sequence match and thus inhibits multiple
target genes. Our recent study with multidrug resistant cancer cells
found that Bcl-2 upregulation and p53 downregulation are
involved in chemoresistance [31]. Thus, inhibition of Bcl-2
function and restoration of p53 simultaneously represents a
promising strategy to overcome drug resistance and improve
Figure 7. Restoration of miR34a inhibits the clonogenic growth and tumorspheres of BxPC-3 cells. BxPC-3 cells were infected with
lentiviral miR-34a expression system (miR-34a) or vector control (MIF), and the infected cells were sorted for GFP positive cells by FACS. The sorted
cells were plated for either colony formation (A) or tumorsphere culture (B) as described in Materials and Methods.* * P,0.01, ***P,0.001, Student’s t-
test, n=3.
doi:10.1371/journal.pone.0006816.g007
Figure 8. miR-34 restoration inhibits the MiaPaCa2 tumor initiation in nude mice. MiaPaCa2 cells were transfected with miR-34a mimic or
NC mimic for 24 hours. Cells were collected and inoculated into female athymic nude mice subcutaneously (s.c.) on both sides of flank, 1610
6 cells/
0.2 ml. The tumor sizes were measured using a caliper (A). Tumor volume was calculated using the formula: (length6width
2)/2. On Day 38, all tumors
were collected to measure the tumor weights (B). C, Picture of the tumors. ***P,0.0001, two-way ANOVA, n=10.
doi:10.1371/journal.pone.0006816.g008
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strategy was explored in the current study, where p53 downstream
target miR-34 was restored in p53-mutant pancreatic cancer
MiaPaCa2 cells with a high level of Bcl-2 and low levels of miR-
34s, resulting in downregulation of Bcl-2 and Notch1-2, together
with the inhibited clonogenic cell growth and invasion; increased
apoptosis and G1 and G2/M arrest in cell cycle; and sensitization
to chemotherapy and radiation. miR-34 restoration could thus re-
build, at least in part, the p53 tumor suppressing signalling
network in pancreatic cancer cells lacking functional p53. This
multi-mode action of miR-34 provides a therapeutic advantage
over the siRNA-based therapies in that miR-34 has multiple
targets, can work on multiple cell signalling pathways at the same
time, leading to synergistic effects which may translate into
improved clinical efficacy for pancreatic cancer patients with p53
deficiency and advanced disease.
Another important finding from the current study is that our data
provide a potential link between the tumor suppressor miR-34 and
the tumor-initiating cells or cancer stem cells. CSCs are a small
subpopulation of cells capable of self-renewal and differentiation
and have been identified in a variety of tumors [29,32,33,34,35].
CSC may be responsible for tumor initiation, progression,
metastasis and resistance to therapy [36,37,38,39]. If this is the
case, it would suggest that cancer therapy should be directed against
both the resting CSC and the proliferating cancer cells [37]. This
may be possible if specific stem cell signals are inhibited using
molecular therapy, while at the same time attacking proliferating
cells by conventional therapies [33,38]. Stem cells are defined by
their ability to undergo self-renewal, as well as multi-lineage
differentiation [40]. Tumorsphere culture has been widely used to
assess the self-renewal potential of stem cells and cancer stem cells
[5,14,32,39]. Our results show that miR-34 restoration caused an
87% reduction of the CD44+/CD133+ tumorsphere-forming and
tumor-initiating CSC in MiaPaCa2 cells with p53 loss of function,
accompanied by a significant inhibition of tumorsphere growth in
vitroandtumorformationinvivo.ThemiR-34-mediatedreductionof
the CD44+/CD133+ CSC is associated with the potent and
simultaneous inhibition of its downstream target genes Notch and
Bcl-2, genes involved in stem cells self-renewal and survival, so-
called ‘‘stem cell genes’’ or ‘‘stemness genes’’ [6,41,42,43]. Here
again, miR-34 shows the advantage of its multi-target potential, as
both stem cell genes Notch and Bcl-2 are inhibited by miR-34 at the
same time, a potent synergy may be achieved in blocking both
Notch signalling pathway andtheanti-apoptotic functionof Bcl-2in
tumor-initiating cells or cancer stem cells. Notch signalling pathway
has been implicated in cancer stem cells [6,44] and has strong
potential as a promising target for pancreatic cancer [45]. It has
been reported that Notch signaling regulates stem cell numbers in
vitro and in vivo [46]. In a brain tumor model, inhibiting the Notch
pathway indeed depleted CD133+ brain cancer stem cells and
blocked tumor initiation [44], consistent with our findings in
pancreatic cancer model. However, our study is the first report
showing that miRNA miR-34 inhibits pancreatic CD44+/CD133+
CSC, potentially via inhibiting downstream target ‘‘stem cell genes’’
such as Notch and Bcl-2. Interestingly, miR-34a and miR-34b are
among the short-list of the stem cell-specific miRNAs discovered by
Dr. Sharp’s group in their pioneer miRNA study [47], supporting
the link of miR-34 to CSC. We are currently carrying out more
detailed mechanism studies to delineate the involvement of Notch
signaling pathway in miR-34-induced inhibition of pancreatic CSC
and its role in chemo/radiosensitization of pancreatic cancer with
p53 loss of function.
According to the CSC model [33,48] that gains increasing
attention recently, for a cancer therapy to be effective and
curative, these highly resistant tumor-initiating cells must be
eliminated. Currently, much research is aimed at identifying the
genetic, epigenetic and protein signatures unique for cancer stem
cells and distinguishing them from non-tumorigenic cells. Our
current study delineates some of those distinguishing characteris-
tics. Our results show that the CD44+/CD133+ MiaPaCa2 cells,
even though only comprising 1–2% of total cell population, have
much higher levels of Bcl-2 and Notch1, and lower levels of miR-
34a,b,c, while CD442/CD1332 cells have levels comparable to
that of total population. miR-34a restoration resulted in an 87%
reduction of the CD44+/CD133+ cells, accompanied by signifi-
cant inhibition of tumorsphere growth in vitro as well as tumor
formation in vivo. More interestingly, this effect was associated with
a 23-fold downregulation of Bcl-2 in the CD44+/CD133+ cells,
while only 43% downregulation in total cells. These data indicate
that the CD44+/CD133+ cells were the target cells of miR-34, i.e.,
miR-34 exerts its tumor-suppressing activity via inhibiting the
CD44+/CD133+ cells. Our results also imply that current gene
expression profiling studies with the total cell population may not
reflect the real genetic signature of the small side-population of
CSC which only comprises 1–2% of total cells. As demonstrated in
our study, one has to isolate the specific CSC population in order
to identify its gene expression signature and to address whether a
molecular therapy is indeed hitting its target(s) in CSC, which has
significant implication in our efforts to discover and develop novel
therapies targeting CSC. Currently, we are using gene and
miRNA arrays with the sorted tumor cells for the genetic and
epigenetic profiling of cancer stem cells.
In conclusion, our study demonstrates that miR-34 may restore,
at least in part, the tumor suppressing function of p53 in p53-
deficient human pancreatic cancer cells. More significantly, miR-
34 restoration inhibits the CD44+/CD133+ tumor-initiating cells
or CSC, accompanied by significant inhibition of tumorsphere
growth in vitro and tumor formation in vivo. Our data provide the
first evidence that miR-34 is involved in pancreatic CSC self-
renewal, potentially via the direct modulation of downstream
targets Notch and Bcl-2. Our results provide novel insight into
how miR-34 works in pancreatic cancer cells with p53 loss of
function. By modulating CSC, the restoration of tumor suppressor
miR-34 may provide a novel therapeutic approach for p53-
deficient pancreatic cancer.
Supporting Information
Figure S1 Characterization of the Zeocin-resistant stable Mia-
PaCa2-miR-34a cells. MiaPaCa2 cells were infected with feline
immunodeficiency virus (FIV) lentiviral system expressing miR-34a
(miR-34a-MIF) or control (MIF), and selected for stable cells by
Zeocin-resistance. A, Western blot shows Bcl-2 protein is down-
regulated in miR-34a-MIF clone. B, qRT-PCR analysis shows that
the target gene Bcl-2 is downregulated in miR-34-MIF clone. C,
Bcl-2 39UTR Luciferase Reporter Assay shows that the miR-34a is
functional in miR-34-MIF clone. Error bar indicates S.D. D, miR-
34a-MIF cells grows slower than MIF control cells. Cells were
plated in a 24-well plate, at every 24 h, cells were harvested in
triplicate wells and the viable cells were counted by Trypan Blue
exclusion. E, Colony formation assay shows the miR-34a inhibits
clonogenic growth of the miR-34-MIF. Cells were seeded in 6-well
plate (200 cells/well) in triplicates. After 12–14 days incubation,
plates were stained with 0.1% crystal violet. Colonies with over 50
cells were counted. **P,0.01, ***P,0.001, Student’s t-test, n=3.
Found at: doi:10.1371/journal.pone.0006816.s001 (1.02 MB TIF)
Figure S2 Restoration of miR-34 inhibits the invasion of
MiaPaCa2 cells. Cell invasion assay was carried out using
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PLoS ONE | www.plosone.org 11 August 2009 | Volume 4 | Issue 8 | e6816Transwells Invasion Kit (Corning Costar) in 24-well tissue culture
plates. A–B. MiaPaCa2 cells were transfected with miR-34a mimic
or NC mimic and placed in the Transwell inserts, cultured for two
days, observed under microscope (A) and quantified (B). C–D. The
stable MiaPaCa2-miR-34a-MIF or MiaPaCa2-MIF cells were
placed in the Transwell inserts, cultured for two days, observed
under microscope (C) and quantified (D).
Found at: doi:10.1371/journal.pone.0006816.s002 (7.60 MB TIF)
Figure S3 Restoration of miR-34 by MIF lentiviral system
inhibited MiaPaCa2 tumorspheres. The stable MiaPaCa2-miR-
34a-MIF or MiaPaCa2-MIF cells were plated for tumorsphere
formation as described in Materials and Methods. 7–10 days later,
tumorspheres were observed under microscope (A) and quantified
(B). C. Quantification of cell numbers per tumorsphere. Tumor-
spheres were collected with a 40 um filter (BD), and dissociated
with trypsin for single cell suspension. Cells were counted with
trypan blue exclusion and data are presented as number of cells
per tumorsphere. **P,0.01, ***P,0.001, Student’s t-test, n=3.
Found at: doi:10.1371/journal.pone.0006816.s003 (3.07 MB TIF)
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